Search research articles
Contact Us
Filters
Showing results (81-90 of 220) with videos related to
Page
of 22
Sort By:
Expert Opinion on Pharmacotherapy
|
April 6, 2002
Fondaparinux versus enoxaparin for the prevention of venous thromboembolism
Sheila A Doggrell
Expert Opinion on Investigational Drugs
|
July 19, 2005
The nitrosterols--a step forward from the steroid anti-inflammatory drugs?
Sheila A Doggrell
Expert Opinion on Investigational Drugs
|
July 19, 2005
New drugs being developed for the treatment of tuberculosis
Sheila A Doggrell
Expert Opinion on Therapeutic Targets
|
August 9, 2005
Neuromedin U--a new target in obesity
Sheila A Doggrell
Current Opinion in Investigational Drugs (London, England : 2000)
|
September 29, 2005
Clinical potential of nitric oxide-independent soluble guanylate cyclase activators
Sheila A Doggrell
Current Opinion in Investigational Drugs (London, England : 2000)
|
April 22, 2006
New targets in and potential treatments for cholesterol gallstone disease
Sheila A Doggrell
Expert Opinion on Pharmacotherapy
|
April 23, 2010
Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
Sheila A Doggrell
Expert Opinion on Pharmacotherapy
|
April 21, 2026
Is supplemental vitamin D useful in the clinically isolated syndrome (CIS) typical of multiple sclerosis?
Sheila A Doggrell
Expert Review of Clinical Pharmacology
|
November 26, 2011
Found in translation: integrated approaches to drug development
Sheila A Doggrell
Expert Opinion on Pharmacotherapy
|
June 4, 2008
Is long-term adjuvant treatment of breast cancer with anastrozole indicated?
Sheila A Doggrell
Page
of 22
Search research articles
Search
Showing results (81-90 of 220) with videos related to
Sort By:
Page
of 22
Expert Opinion on Pharmacotherapy
|
April 6, 2002
Fondaparinux versus enoxaparin for the prevention of venous thromboembolism
Sheila A Doggrell
Expert Opinion on Investigational Drugs
|
July 19, 2005
The nitrosterols--a step forward from the steroid anti-inflammatory drugs?
Sheila A Doggrell
Expert Opinion on Investigational Drugs
|
July 19, 2005
New drugs being developed for the treatment of tuberculosis
Sheila A Doggrell
Expert Opinion on Therapeutic Targets
|
August 9, 2005
Neuromedin U--a new target in obesity
Sheila A Doggrell
Current Opinion in Investigational Drugs (London, England : 2000)
|
September 29, 2005
Clinical potential of nitric oxide-independent soluble guanylate cyclase activators
Sheila A Doggrell
Current Opinion in Investigational Drugs (London, England : 2000)
|
April 22, 2006
New targets in and potential treatments for cholesterol gallstone disease
Sheila A Doggrell
Expert Opinion on Pharmacotherapy
|
April 23, 2010
Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
Sheila A Doggrell
Expert Opinion on Pharmacotherapy
|
April 21, 2026
Is supplemental vitamin D useful in the clinically isolated syndrome (CIS) typical of multiple sclerosis?
Sheila A Doggrell
Expert Review of Clinical Pharmacology
|
November 26, 2011
Found in translation: integrated approaches to drug development
Sheila A Doggrell
Expert Opinion on Pharmacotherapy
|
June 4, 2008
Is long-term adjuvant treatment of breast cancer with anastrozole indicated?
Sheila A Doggrell
Page
of 22